Project Grant HT94252510912
Award Date 9/1/25
Completion Date 8/31/28
Dollars Obligated $2.6M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Spencerville, MD 20868, USA
Similar Awards
- The Defense Health Agency awarded a $1,973,398 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to Azevan Pharmaceuticals Inc. in Bethlehem, PA. The grant supports the development of a new drug to prevent the effects of mild traumatic brain injury (TBI) or concussion. The research project will be conducted over a 2-year period from June 2024 to June 2026. The goal is to advance the development of an innovative medical solution to address this critical...
- The Defense Health Agency awarded The Roskamp Institute, Inc. a $817,085 Project Grant under the Military Medical Research and Development program to conduct research on amnion cell secretome-mediated therapy for traumatic brain injury. The three-year award runs from June 1, 2023 to May 31, 2026 and will support The Roskamp Institute's investigation into potential therapies using amnion-derived cell treatments to address neuroinflammation and other vascular contributions to traumatic brain...
- The U.S. Defense Health Agency awarded a $817,200 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Roskamp Institute, Inc. in Sarasota, Florida. The grant, awarded on September 1, 2024, will support a 3-year research project titled "Targeting APOE Bioenergetics for Reducing the Risk of Neurodegeneration After Chronic Traumatic Brain Injury." The research aims to investigate mitochondrial bioenergetics, tau protein pathology,...
- This Project Grant award of $1,332,764.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) is funding the "Therapeutic Development of NC101 for Promoting Neurological Recovery After Chronic SCI" by Neurocreis, Inc. in College Station, TX. The award, which runs from July 1, 2025 to June 30, 2028, supports advanced biomedical research aimed at developing innovative medical solutions to address critical health challenges for military...
- This $691,213 Project Grant from the Department of the Army Medical Command, under the Military Medical Research and Development program (CFDA 12.420), supports research into bioengineered 3D human brain systems to investigate risk factors, mechanisms, and treatments for traumatic brain injury-induced Alzheimer's disease. Tufts University is the primary awardee and will conduct research. Massachusetts General Hospital will provide $691,213 in research services as a sub-awardee. The overarching...
- The Defense Health Agency awarded a $1,131,357 Project Grant titled "MicroRNA Biomarkers of Cumulative Blast-Mild Traumatic Brain Injury (Micro BCB)" under the Military Medical Research and Development (CFDA 12.420) program. The grant supports research conducted by the Seattle Institute for Biomedical and Clinical Research, a non-profit institute, to investigate the use of microRNA biomarkers for detecting and monitoring the impact of mild traumatic brain injury related to blast...
- The federal Project Grant award in the amount of $564,901.00, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research to develop a drug delivery strategy using exosomes as nanocarriers to target the brainstem. This multi-year award, with a project period from September 1, 2024 to August 31, 2027, will be performed by the Mayo Clinic, a leading non-profit academic medical center. The research aims to explore innovative...
- This $6,214,900 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program supports research on the role of genetic risk factors and immune response on neurovascular unit (NVU) function in post-traumatic brain injury (TBI) cognitive impairment. The primary awardee, the Scintillon Institute, a non-profit biomedical research organization in San Diego, California, will conduct this advanced scientific investigation over...
- The Defense Health Agency awarded a $3.755 million Project Grant to the University of Wisconsin-Madison through the Military Medical Research and Development program (CFDA 12.420) to investigate dual orexin antagonist treatment to prevent neurobehavioral sequelae of traumatic brain injury from April 1, 2023 to March 31, 2027. The Military Medical Research and Development program supports innovative medical research to improve warfighter health and transform public healthcare. Under this award,...
- The Defense Health Agency awarded a $1,633,104 Project Grant to The Roskamp Institute, Inc. under the Military Medical Research and Development program (CFDA 12.420) to develop highly selective DYRK1A inhibitors as a novel therapeutic approach for traumatic brain injury. The grant, which runs from June 15, 2024 to June 14, 2028, supports the organization's research to understand the causes of and find cures for neuropsychiatric and neurodegenerative disorders. The Roskamp Institute, a non-profit...